| 朝陽科技大學 |
2018-04 |
OSGi-based IP Multimedia Subsystem Services Gateway
|
Chang, Yi-Chun; Li, Jian-Wei; Lv, Jing-Hong |
| 國立成功大學 |
2011-02-15 |
OSGi-based services architecture for Cyber-Physical Home Control Systems
|
Lai, Chin-Feng; Ma, Yi-Wei; Chang, Sung-Yen; Chao, Han-Chieh; Huang, Yueh-Min |
| 國立成功大學 |
2012-11-15 |
OSGi-based smart home architecture for heterogeneous network
|
Cheng, Sheng-Tzong; Wang, Chi-Hsuan; Horng, Gwo-Jiun |
| 中山醫學大學 |
2015-07-01 |
OSGIN1蛋白及脂筏在n-3、n-6多元不飽和脂肪酸調控人類乳癌細胞生長、轉移及自噬作用扮演之角色及其分子機制
|
李健群 |
| 中山醫學大學 |
2015 |
OSGIN1蛋白及脂筏在n-3、n-6多元不飽和脂肪酸調控人類乳癌細胞生長、轉移及自噬作用扮演之角色及其分子機制
|
李健群 |
| 國立成功大學 |
2006-06-14 |
OSGi平台上輕量射頻辨識系統及可抽換式RFID元件
|
吳政穎; Wu, Zheng-Ying |
| 國立成功大學 |
2007-01-25 |
OSGi平台之動態偵防系統
|
黃啟智; Huang, Chi-Chih |
| 國立成功大學 |
2007-07-12 |
OSGi數位家庭閘道上設計與實作隨家庭成員生活習慣演進之學習與反應框架
|
張聖安; Chang, Sheng-An |
| 國立成功大學 |
2011 |
OSGi服務平台之自動化資源管理架構
|
侯廷偉 |
| 樹德科技大學 |
2005 |
OSGi開放式服務平台與MHP內崁式互動電視接收器之整合機制研究與分析
|
林政良; Cheng-Liang Lin |
| 國立成功大學 |
2008-07-14 |
OSGi閘道器與服務經營者間含資源限制考量之服務部署與恢復策略
|
王純茗; Wang, Chun-Ming |
| 臺大學術典藏 |
2020-05-26T09:26:30Z |
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
|
Ramalingam S.S; CHIH-HSIN YANG; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A.; J?nne P.A.;Thress K.S;Barrett J.C;Markovets A;Stetson D;Ghiorghiu S;Rukazenkov Y;Mann H;Ohe Y;Nogami N;John T;Kim D.-W;Kurata T;Lee C.K;Chih-Hsin Yang;Ramalingam S.S |
| 臺大學術典藏 |
2020-07-07T08:21:02Z |
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
|
Kim, Tae Min; Goldman, Jonathan W.; Natale, Ronald B.; Brown, Andrew P.; Collins, Barbara; Chmielecki, Juliann; Vishwanathan, Karthick; Mendoza-Naranjo, Ariadna; Ahn, Myung-Ju; Stathes Paganis; Lee, Dae H.; Ahn, Jin-Seok; Yang, James C.H.; Kim, Sang-We; Kim, Dong-Wan; Lee, Jong-Seok; Cho, Byoung Chul; Yang, James C.H.;Kim, Sang-We;Kim, Dong-Wan;Lee, Jong-Seok;Cho, Byoung Chul;Ahn, Jin-Seok;Lee, Dae H.;Kim, Tae Min;Goldman, Jonathan W.;Natale, Ronald B.;Brown, Andrew P.;Collins, Barbara;Chmielecki, Juliann;Vishwanathan, Karthick;Mendoza-Naranjo, Ariadna;Ahn, Myung-Ju |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study
|
Chih-Hsin Yang;Kim S.-W.;Kim D.-W.;Lee J.-S.;Cho B.C.;Ahn J.-S.;Lee D.H.;Kim T.M.;Goldman J.W.;Natale R.B.;Brown A.P.;Collins B.;Chmielecki J.;Vishwanathan K.;Mendoza-Naranjo A.;Ahn M.-J.; CHIH-HSIN YANG; Kim S.-W.; Kim D.-W.; Lee J.-S.; Cho B.C.; Ahn J.-S.; Lee D.H.; Kim T.M.; Goldman J.W.; Natale R.B.; Brown A.P.; Collins B.; Chmielecki J.; Vishwanathan K.; Mendoza-Naranjo A.; Ahn M.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Osimertinib in patients with T790M mutation-positive, advanced non?�small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies
|
Ahn M.-J;Tsai C.-M;Shepherd F.A;Bazhenova L;Sequist L.V;Hida T;Chih-Hsin Yang;Ramalingam S.S;Mitsudomi T;Jnne P.A;Mann H;Cantarini M;Goss G.; Ahn M.-J; Tsai C.-M; Shepherd F.A; Bazhenova L; Sequist L.V; Hida T; CHIH-HSIN YANG; Ramalingam S.S; Mitsudomi T; Jnne P.A; Mann H; Cantarini M; Goss G. |
| 臺大學術典藏 |
2021-04-23T05:56:33Z |
Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies
|
Ahn M.-J.;Han J.-Y.;Kim D.-W.;Cho B.C.;Kang J.-H.;Kim S.-W.;Chih-Hsin Yang;Mitsudomi T.;Lee J.S.; Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG; Mitsudomi T.; Lee J.S. |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A. |
| 臺大學術典藏 |
2017 |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Chia-Chi Lin;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Yang J.C.-H; Yang J.C.-H; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Chia-Chi Lin; Mann H; Cantarini M; Ghiorghiu S; J?nne P.A. |
| 臺大學術典藏 |
2021-05-02T03:29:23Z |
Osimertinib in resected EGFR-mutated non–small-cell lung cancer
|
Wu Y.-L.;Tsuboi M.;He J.;John T.;Grohe C.;Majem M.;Goldman J.W.;Laktionov K.;Kim S.-W.;Kato T.;Vu H.-V.;Lu S.;Lee K.-Y.;Akewanlop C.;Chong-Jen Yu;De Marinis F.;Bonanno L.;Domine M.;Shepherd F.A.;Zeng L.;Hodge R.;Atasoy A.;Rukazenkov Y.;Herbst R.S.; Wu Y.-L.; Tsuboi M.; He J.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. |
| 臺大學術典藏 |
2022-06-27T06:59:40Z |
Osimertinib in resected EGFR-mutated non–small-cell lung cancer
|
Wu Y.-L.; Tsuboi M.; He J.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M?�Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
|
Chih-Hsin Yang;Shepherd F.A;Kim D.-W;Lee G.-W;Lee J.S;Chang G.-C;Lee S.S;Wei Y.-F;Lee Y.G;Laus G;Collins B;Pisetzky F;Horn L.; Chih-Hsin CHIH-HSIN YANG; Shepherd F.A; Kim D.-W; Lee G.-W; Lee J.S; Chang G.-C; Lee S.S; Wei Y.-F; Lee Y.G; Laus G; Collins B; Pisetzky F; Horn L. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist L.V.;Han J.-Y.;Ahn M.-J.;Cho B.C.;Yu H.;Kim S.-W.;Chih-Hsin Yang;Lee J.S.;Su W.-C.;Kowalski D.;Orlov S.;Cantarini M.;Verheijen R.B.;Mellemgaard A.;Ottesen L.;Frewer P.;Ou X.;Oxnard G.; Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. |
| 國立成功大學 |
2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist, L.V.;Han, J.-Y.;Ahn, M.-J.;Cho, B.C.;Yu, H.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.S.;Su, W.-C.;Kowalski, D.;Orlov, S.;Cantarini, M.;Verheijen, R.B.;Mellemgaard, A.;Ottesen, L.;Frewer, P.;Ou, X.;Oxnard, G. |
| 中山醫學大學 |
2021 |
Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan
|
Chang, G; Shih, J; Chao, H; Yang, C; Lin, C; Hung, J; Hsiao, S; Wang, C; Chian, C; Hsia, T; Yu, C; Chen, Y |
| 國立成功大學 |
2020 |
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
|
Papadimitrakopoulou, V.A.;Mok, T.S.;Han, J.-Y.;Ahn, M.-J.;Delmonte, A.;Ramalingam, S.S.;Kim, S.W.;Shepherd, F.A.;Laskin, J.;He, Y.;Akamatsu, H.;Theelen, W.S.M.E.;Su, W.-C.;John, T.;Sebastian, M.;Mann, H.;Miranda, Miranda M.;Laus, G.;Rukazenkov, Y.;Wu, Y.-L. |
